{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:16:09Z","timestamp":1780974969568,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03934-8","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:01:49Z","timestamp":1752156109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PD-1\/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Jianfei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"1","key":"3934_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"3934_CR2","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.2008.19.4522","volume":"27","author":"YY Soon","year":"2009","unstructured":"Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277\u201383.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3934_CR3","first-page":"84","volume":"74","author":"KK Kondo","year":"2024","unstructured":"Kondo KK, Rahman B, Ayers CK, Relevo R, Griffin JC, Halpern MT. Lung cancer diagnosis and mortality beyond 15 years since quit in individuals with a 20\u2009+\u2009pack-year history: A systematic review. CA Cancer J Clin. 2024;74(1):84\u2013114.","journal-title":"CA Cancer J Clin"},{"key":"3934_CR4","doi-asserted-by":"publisher","first-page":"105607","DOI":"10.1016\/j.ebiom.2025.105607","volume":"113","author":"Z Huang","year":"2025","unstructured":"Huang Z, Karabou\u00e9 A, Zeng L, Lecoeuvre A, Zhang L, Li XM, et al. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study. EBioMedicine. 2025;113:105607.","journal-title":"EBioMedicine"},{"key":"3934_CR5","doi-asserted-by":"publisher","first-page":"175883592412556","DOI":"10.1177\/17588359241255613","volume":"16","author":"W Tian","year":"2024","unstructured":"Tian W, Niu L, Shi Y, Li S, Zhou R. First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis. Ther Adv Med Oncol. 2024;16:17588359241255613.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3934_CR6","doi-asserted-by":"publisher","first-page":"e15535","DOI":"10.1111\/1759-7714.15535","volume":"16","author":"K Kim","year":"2025","unstructured":"Kim K, Sweeting M, J\u00f6nsson L, Wilking N. Long-Term Real-World survival of immunotherapy compared to chemotherapy for metastatic nonsmall cell lung cancer: A propensity Score-Matched analysis. Thorac Cancer. 2025;16(1):e15535.","journal-title":"Thorac Cancer"},{"issue":"11","key":"3934_CR7","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous Non-Small-Cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3934_CR8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy in squamous Non-Small-Cell lung cancer: 5-Year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3934_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3934_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodr\u00edguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and Nab-Paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351\u201360.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3934_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","volume":"23","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;23(2):220\u201333.","journal-title":"Lancet Oncol"},{"key":"3934_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","volume":"171","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. Lung Cancer. 2022;171:56\u201360.","journal-title":"Lung Cancer"},{"issue":"10","key":"3934_CR13","doi-asserted-by":"publisher","first-page":"103728","DOI":"10.1016\/j.esmoop.2024.103728","volume":"9","author":"S Lu","year":"2024","unstructured":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ma Z, et al. Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial). ESMO Open. 2024;9(10):103728.","journal-title":"ESMO Open"},{"issue":"4","key":"3934_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.21037\/tlcr-20-246","volume":"9","author":"S Peng","year":"2020","unstructured":"Peng S, Ying AF, Tai BC, Soo RA. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. Transl Lung Cancer Res. 2020;9(4):1124\u201337.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3934_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"3934_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"4","key":"3934_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the journal of clinical epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3934_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","volume":"12","author":"H Zhong","year":"2024","unstructured":"Zhong H, Sun S, Chen J, Wang Z, Zhao Y, Zhang G, et al. First-line penpulimab combined with Paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024;12(5):355\u201365.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"3934_CR19","doi-asserted-by":"publisher","first-page":"e009240","DOI":"10.1136\/jitc-2024-009240","volume":"12","author":"C Zhou","year":"2024","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the camel randomized phase 3 study. J Immunother Cancer. 2024;12(11):e009240.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3934_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as First-Line treatment for advanced nonsquamous NSCLC: extended Follow-Up of camel phase 3 trial. J Thorac Oncol. 2023;18(5):628\u201339.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3934_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305\u201314.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"3934_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab plus carboplatin and Paclitaxel as First-Line treatment for advanced squamous NSCLC (CameL-Sq): A phase 3 trial. J Thorac Oncol. 2022;17(4):544\u201357.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3934_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","volume":"9","author":"J Zhong","year":"2024","unstructured":"Zhong J, Fei K, Wu L, Li B, Wang Z, Cheng Y, et al. Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2024;9(1):369.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"3934_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","volume":"41","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, et al. Toripalimab plus chemotherapy for patients with Treatment-Naive advanced Non-Small-Cell lung cancer: A multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023;41(3):651\u201363.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3934_CR25","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cam4.5144","volume":"12","author":"S Lu","year":"2023","unstructured":"Lu S, Fang J, Wang Z, Fan Y, Liu Y, He J, et al. Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Med. 2023;12(3):2666\u201376.","journal-title":"Cancer Med"},{"issue":"10","key":"3934_CR26","first-page":"100225","volume":"2","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, et al. Pembrolizumab plus chemotherapy for Chinese patients with metastatic squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep. 2021;2(10):100225.","journal-title":"JTO Clin Res Rep"},{"issue":"12","key":"3934_CR27","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol. 2021;16(12):2109\u201320.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"3934_CR28","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, Double-Blind, phase 3 study (Oncology pRogram by innovent anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636\u201346.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3934_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab plus platinum and gemcitabine as First-Line treatment for advanced or metastatic squamous NSCLC: results from a randomized, Double-Blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501\u201311.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3934_CR30","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","volume":"16","author":"S Lu","year":"2021","unstructured":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, et al. Tislelizumab plus chemotherapy as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512\u201322.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"3934_CR31","doi-asserted-by":"publisher","first-page":"103727","DOI":"10.1016\/j.esmoop.2024.103727","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Lu S, Yu X, Hu Y, Zhao J, Sun M, et al. Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. ESMO Open. 2024;9(10):103727.","journal-title":"ESMO Open"},{"issue":"5","key":"3934_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as First-line treatment for advanced squamous Non-Small-Cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2021;7(5):709\u201317.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3934_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","volume":"20","author":"S Peters","year":"2025","unstructured":"Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without Tremelimumab in combination with chemotherapy in First-Line metastatic NSCLC: Five-Year overall survival outcomes from the phase 3 POSEIDON trial. J Thorac Oncol. 2025;20(1):76\u201393.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3934_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.20892\/j.issn.2095-3941.2020.0121","volume":"17","author":"R Jin","year":"2020","unstructured":"Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, et al. Molecular heterogeneity of anti-PD-1\/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biol Med. 2020;17(3):768\u201381.","journal-title":"Cancer Biol Med"},{"issue":"7","key":"3934_CR35","doi-asserted-by":"publisher","first-page":"e247021","DOI":"10.6004\/jnccn.2024.7021","volume":"22","author":"K Miura","year":"2024","unstructured":"Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, et al. Ancestry-, Sex-, and Age-Based differences of gene alterations in NSCLC: from the Real-World data of Cancer genomic profiling tests. J Natl Compr Canc Netw. 2024;22(7):e247021.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"3934_CR36","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.21037\/tlcr-24-964","volume":"13","author":"H Zhou","year":"2024","unstructured":"Zhou H, Zeng Y, Hida T, Hsu R, Huang Y, Dong X. The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review. Transl Lung Cancer Res. 2024;13(12):3778\u201394.","journal-title":"Transl Lung Cancer Res"},{"key":"3934_CR37","doi-asserted-by":"publisher","unstructured":"Jiang S, Guo F, Li L. Biological mechanisms and immunotherapy of brain metastases in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer 2025 Apr 10:189320. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189320","DOI":"10.1016\/j.bbcan.2025.189320"},{"issue":"2","key":"3934_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.21037\/jtd-24-1495","volume":"17","author":"X Yan","year":"2025","unstructured":"Yan X, Wang Y, Wu F, Zhou G, Shen J, Yu S. Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study. J Thorac Dis. 2025;17(2):859\u201371.","journal-title":"J Thorac Dis"},{"issue":"7","key":"3934_CR39","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.21037\/tlcr-23-245","volume":"12","author":"AE Cali Daylan","year":"2023","unstructured":"Cali Daylan AE, Halmos B. Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the Tale of the tail. Transl Lung Cancer Res. 2023;12(7):1636\u201342.","journal-title":"Transl Lung Cancer Res"},{"key":"3934_CR40","doi-asserted-by":"crossref","unstructured":"Li Y, Ji L, Zhang Y, Zhang J, Reuben A, Zeng H et al. The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer. MedComm (2020). 2024;5(6):e604.","DOI":"10.1002\/mco2.604"},{"issue":"6","key":"3934_CR41","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/cancers17061027","volume":"17","author":"MS Oh","year":"2025","unstructured":"Oh MS, Abascal J, Rennels AK, Salehi-Rad R, Dubinett SM, Liu B. Tumor heterogeneity and the immune response in Non-Small cell lung cancer: emerging insights and implications for immunotherapy. Cancers (Basel). 2025;17(6):1027.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3934_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/0008-5472.CAN-24-1484","volume":"85","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Song X, Feng Y, Qian Y, Chen B, Zhang T, et al. The circrna cEMSY induces Immunogenic cell death and boosts immunotherapy efficacy in lung adenocarcinoma. Cancer Res. 2025;85(3):497\u2013514.","journal-title":"Cancer Res"},{"key":"3934_CR43","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","volume":"11","author":"P De Cicco","year":"2020","unstructured":"De Cicco P, Ercolano G, Ianaro A. The new era of Cancer immunotherapy: targeting Myeloid-Derived suppressor cells to overcome immune evasion. Front Immunol. 2020;11:1680.","journal-title":"Front Immunol"},{"issue":"9","key":"3934_CR44","first-page":"100532","volume":"4","author":"EB Ulas","year":"2023","unstructured":"Ulas EB, Hashemi SMS, Houda I, Kaynak A, Veltman JD, Fransen MF, et al. Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC. JTO Clin Res Rep. 2023;4(9):100532.","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"3934_CR45","doi-asserted-by":"publisher","first-page":"e007305","DOI":"10.1136\/jitc-2023-007305","volume":"11","author":"M Chen","year":"2023","unstructured":"Chen M, Ma P, Zhang Y, Wang D, Yu Z, Fu Y, et al. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma. J Immunother Cancer. 2023;11(10):e007305.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3934_CR46","doi-asserted-by":"publisher","first-page":"30983","DOI":"10.1038\/s41598-024-82105-3","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Chen J, Tsai N, Zhu X, Zhao M, Meng L, et al. Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors. Sci Rep. 2024;14(1):30983.","journal-title":"Sci Rep"},{"issue":"3","key":"3934_CR47","doi-asserted-by":"publisher","first-page":"e1613","DOI":"10.1002\/ctm2.1613","volume":"14","author":"X Lin","year":"2024","unstructured":"Lin X, Xie M, Yao J, Ma X, Qin L, Zhang XM, et al. Immune-related adverse events in non-small cell lung cancer: occurrence, mechanisms and therapeutic strategies. Clin Transl Med. 2024;14(3):e1613.","journal-title":"Clin Transl Med"},{"issue":"1","key":"3934_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","volume":"39","author":"XH Jia","year":"2020","unstructured":"Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3934_CR49","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10637-022-01232-8","volume":"40","author":"LF Meng","year":"2022","unstructured":"Meng LF, Huang JF, Luo PH, Huang SX, Wang HL. The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. Invest New Drugs. 2022;40(4):810\u20137.","journal-title":"Invest New Drugs"},{"issue":"2","key":"3934_CR50","doi-asserted-by":"publisher","first-page":"e0276318","DOI":"10.1371\/journal.pone.0276318","volume":"19","author":"J Kang","year":"2024","unstructured":"Kang J, Zhang J, Tian Z, Xu Y, Li J, Li M. The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. PLoS ONE. 2024;19(2):e0276318.","journal-title":"PLoS ONE"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03934-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03934-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03934-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:52:33Z","timestamp":1757231553000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03934-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3934"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03934-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"CRD420251038720.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"PROSPERO registration ID"}},{"value":".","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Link"}},{"value":"Due to the nature of this study no ethical approval was required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}},{"value":"The authors certify that there is no conflict of interest regarding this manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"273"}}